Xeltis’ closing of the Series B financing was featured in the French magazine Biotech Finances. The article mainly describes the investment’s great value to fund market access activities for Xeltis’ first product, the pulmonary valve, and the development of the company’s product pipeline. In the article, our CEO and Board member, Laurent Grandidier, our Board member, Vanessa Malier explain Xeltis’ potential to overcome current standards of care. The investment marks a significant milestone for Xeltis on its mission to improve lives of patients.
